|c-di-AMP Catalog No.GC13643|
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
|Chemical Name||(2R,3S,3aS,7aS,9R,10aS,14aS)-2,9-bis(6-amino-9H-purin-9-yl)-3,5,10,12-tetrahydroxydecahydrodifuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine 5,12-dioxide|
|Solubility||Soluble in DMSO||Storage||Desiccate at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
c-di-AMP (Cyclic diadenylate) signaling is a central factor in many Gram-positive bacteria regulating cell wall synthesis, potassium ion channels, DNA repair, and biofilm formation. c-di-AMP is also essential for cell growth, survival, and virulence of several well-known human pathogenic bacteria including S. aureus, L. monocytogenes, S. pyogenes, and Mycobacterium spp.c-di-AMP (Cyclic diadenylate) combines with model antigens, such as OVA or β-Gal, acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
. Fahmi T, et al. c-di-AMP: An Essential Molecule in the Signaling Pathways that Regulate the Viability and Virulenceof Gram-Positive Bacteria. Genes (Basel). 2017 Aug 7;8(8).
. Ning H, et al. Recombinant BCG With Bacterial Signaling Molecule Cyclic di-AMP as Endogenous AdjuvantInduces Elevated Immune Responses After Mycobacterium tuberculosis Infection. Front Immunol. 2019 Jul 3;10:1519.
. Ebensen T, et al. The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and QualitativeEnhanced Immune Responses Post Immunization. Front Cell Infect Microbiol. 2019 Feb 19;9:31.
. Sanchez MV, et al. Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellularimmune responses and provides protection against virus challenge. PLoS One. 2014 Aug 20;9(8):e104824.